Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for abuse.

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...